Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE versus PHENETRON.
Cetirizine vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective second-generation H1-receptor antagonist that inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
10 mg orally once daily; 5 mg orally once daily for mild symptoms
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 8.3 hours in healthy adults; extended to 20 hours in elderly and patients with renal impairment
Clinical Note
moderateCetirizine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate."
Clinical Note
moderateLevocetirizine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Cyclosporine
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Primarily renal (60% unchanged in urine); minor biliary/fecal (10%)
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category A/B
Category C
Antihistamine
Antihistamine
"The metabolism of Cyclosporine can be decreased when combined with Levocetirizine."